Alternative splicing of human peroxisome proliferator-activated receptor delta (PPARdelta):effects on translation efficiency and trans-activation ability by Kerstin Lundell et al.
BioMed CentralBMC Molecular Biology
ssOpen AcceResearch article
Alternative splicing of human peroxisome proliferator-activated 
receptor delta (PPARdelta):effects on translation efficiency and 
trans-activation ability
Kerstin Lundell*†, Petra Thulin†, Anders Hamsten and Ewa Ehrenborg*
Address: The Atherosclerosis Research Unit, King Gustaf V Research Institute, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Email: Kerstin Lundell* - Kerstin.Lundell@ki.se; Petra Thulin - Petra.Thulin@ki.se; Anders Hamsten - Anders.Hamsten@ki.se; 
Ewa Ehrenborg* - Ewa.Ehrenborg@ki.se
* Corresponding authors    †Equal contributors
Abstract
Background: Peroxisome proliferator-activated receptor delta (PPARδ) is a member of the
nuclear receptor superfamily. Numerous studies have aimed at unravelling the physiological role of
PPARδ as a transcriptional regulator whereas the regulation of PPARδ gene expression has been
less studied.
Results: The principal transcription start site in the human PPARδ gene identified here is
positioned upstream of exon 1, although four alternative 5'-ends related to downstream exons
were identified. The demonstration of multiple 5'-UTR splice variants of PPARδ mRNA, with an
impact on translation efficiency, suggests a translational regulation of human PPARδ expression.
Five untranslated exons identified in this study contribute to the variability among the 5'-UTRs of
human PPARδ mRNAs. Moreover, in vitro studies of a 3'-splice transcript encoding a truncated
variant of PPARδ (designated PPARδ2) show that this isoform constitutes a potential dominant
negative form of the receptor.
Conclusion: We propose that alternative splicing of human PPARδ constitutes an intrinsic role
for the regulation of PPARδ expression and thus activity, and highlight the significance of alternative
splicing of this nuclear receptor in physiology and disease.
Background
Peroxisome proliferator-activated receptors (PPARs) are
ligand-dependent transcription factors that activate target
genes by binding to peroxisome proliferator response ele-
ments (PPREs) as heterodimers with the retinoid × recep-
tor (RXR) (NR2B). Three PPAR isoforms encoded by
different genes have been identified: α (PPARα or
NR1C1), δ/β (PPARδ or NR1C2) and γ (PPARγ or
NR1C3). The functional specificity among members of
the PPAR subfamily is achieved by isoform-specific tissue
expression as well as ligand binding specificity [1-5].
Endogenous ligands that activate PPARs are polyunsatu-
rated fatty acids or their derivatives [6-8]. Ligand activa-
tion of PPARs induces conformational changes that
promote binding of co-activators that are essential for the
trans-activating function whereas binding of nuclear co-
repressors is associated with transcriptional repression.
PPARδ is the only isoform that maintains repressor activ-
ity when bound to DNA. It has been reported that unli-
gated PPARδ can act as an intrinsic transcription repressor
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12]. Given that the PPARδ gene is ubiquitously expressed
this suggests an additional role for PPARδ as a receptor
whose relative level of expression can be used to repress
the expression of PPRE target genes.
It was not until recently that the roles of PPARδ were dis-
closed through utilization of specific ligands together with
relevant cells and animal models. PPARδ controls various
physiological functions including lipid and glucose
homeostasis, inflammation, cell proliferation and differ-
entiation [13]. PPARδ-deficiency in mice negatively affects
growth, adipose stores, epidermal cell proliferation, and
myelinisation of corpus callosum [14,15]. Treatment of
insulin-resistant obese rhesus monkeys with a PPARδ spe-
cific ligand has been shown to promote cholesterol efflux,
increase HDL levels and decrease LDL, triglyceride and
insulin levels [16]. Further, PPARδ is highly expressed in
skeletal muscle, and treatment with PPARδ specific lig-
ands increases the proportion of oxidative slow-twitch
myofibers and induces expression of genes involved in
fatty acid utilization and oxidation as well as glucose
uptake and metabolism [17-24].
Little is so far known considering how the expression of
PPARδ itself is regulated. Here we report on new 5'-
untranslated exons and multiple 5'-UTRs of PPARδ mRNA
transcripts, with an impact on the translation efficiency.
In addition, we report on the expression of a 3'-splice var-
iant of human PPARδ (PPARδ2), encoding a potential
dominant negative regulator of gene expression. Since
alternative splicing contributes to the regulation of gene
expression and constitutes an important source of evolu-
tionary diversity, we hypothesize that spliced mRNA iso-
forms of human PPARδ play a role in controlling its
function.
Results
Multiple untranslated exons and alternative transcription 
start sites
We have previously reported the human PPARδ gene to
encompass 9 exons of which exons 1–3, the 5'-end of
exon 4 and the 3'-end of exon 9 are untranslated [25]. An
investigation was conducted aiming to identify possible
alternative 5'-ends in transcripts of PPARδ. Five new 5'-
untranslated exons in alternatively spliced transcripts of
human PPARδ mRNA were identified. The locations of
these exons (designated exons 2a – 2e) in the gene
sequence are outlined in Figure 1A. The newly identified
exons were found at different time-points during the
investigation and were subsequently re-annotated to indi-
cate the relative position of each exon in the gene. Exons
2a, 2c and 2e were originally found by 5'-RACE using Mar-
athon cDNAs from placenta, adipose tissue and pancreas.
Combinations of these exons, including differently
spliced forms of exon 2a, were found to be spliced-in gen-
erating a variety of 5'-UTRs, as displayed in Figure 1B.
Exons 2b and 2d were subsequently found among
sequenced PCR fragments generated using Marathon
cDNAs and cell-derived cDNAs as templates and different
combinations of 5'-untranslated exon-specific primers.
The genomic locations and sequences of the splice junc-
tions of spliced-in exons are summarized in Table 1. None
of the 5'-UTRs found in this study contains any new in-
frame coding regions. Thus, the open reading frame
(ORF) region encoded by exons 4 to 9 remains identical
in all 5'-spliced transcripts.
The majority of the 5'-splice PPARδ transcripts contain
exon 1 in the 5'-end. However, alternative 5'-ends associ-
ated with exons 2a, 2c and 2e were found, which is illus-
trated in Figure 1B, 5'-UTRs: H-K. Of these, the alternative
5'-end containing full-length exon 2c was found only in
pancreas (Figure 1B, 5'-UTR: I) whereas the others could
be found in all three Marathon cDNAs. The genomic loca-
tions and sequences of the alternative 5'-end exons are
summarized in Table 2.
A bioinformatic approach to identify splice variants of
human PPARδ using the NCBI human Genome Browser
and the human EST-search tool, indeed, showed the pres-
ence of exons 2a, 2b, 2c and 2d among 5'-spliced tran-
scripts of PPARδ, all with exons 1 and/or 2 upstream.
Table 1: Sequences of splice junctions of newly identified spliced-in exons in the 5'-UTR of human PPARδ
Spliced-in exon Size (bp) Genomic position
 downstream of exon 2 (bp)
3'-splice acceptor 5'-splice donor
2a 641 1212 ctgcagGGGTAG TCGCAGgtagga
2b 119 4427 agatagCATCTC CTACAGgtatgt
2c 122 5778 tctcagGACCAG TGTGAGgtaatg
2d 315 36426 atctagGAGGTG TGGGAAgtgagg
2e 115 49826 tttcagATTATC TGTCCTgtgagt
The genomic positions of exons were deduced using the human PPARδ RefSeq [GenBank: NM_006238]. Upper-case and lower-case letters indicate 
exon and intron sequences, respectively. The consensus splice donor-acceptor sequences are in bold letters.Page 2 of 17
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Table 2: Sequences of identified alternative 5'-end exons in 5'-UTRs of human PPARδ transcripts
5'-end exon Size (bp) Genomic position 
downstream of exon 2 (bp)
5'-end 5'-splice donor
2a 79 1774 CCCAGTGGCAGC TCGCAGgtagga
2c 883 5017 GCCAGTTCTTTT TGTGAGgtaatg
2c 318 5582 CTTGATGCTGTT TGTGAGgtaatg
2e 180 49761 CAACCTCCCTGC TGTCCTgtgagt
The genomic positions of exons were deduced using the human PPARδ RefSeq [GenBank: NM_006238]. Upper-case and lower-case letters 
indicate exon and intron sequences, respectively. The consensus splice donor sequences are in bold letters. The relative positions of 5'-ends in the 
gene are also illustrated in Figure 1B, 5'-UTRs denoted H-K.
Structure and chromosomal location of the human PPARδ geneFigure 1
Structure and chromosomal location of the human PPARδ gene. A. A physical map of the 85 kb human 6p21.31 
region. The locations of exons are outlined with the previously known exons (denoted in upper row) and newly identified 
exons (denoted in lower row) indicated. The genomic positions of the new exons were deduced by comparing their sequences 
to that of the human PPARδ gene [GenBank: NM_006238]. The sequences of splice junctions and alternative 5'-ends related to 
these exons are outlined in Tables 1 and 2, respectively. B. A schematic representation of the PPARδ gene showing coding 
exons (white boxes), previously reported untranslated exons or part of exons (grey boxes), and herein identified untranslated 
exons (black boxes). The analysed and discussed variety of splicing among untranslated exons and alternative 5'-ends identified 
by Marathon 5'-RACE as described in "Methods" is shown below the gene (5'-UTRs: A-K).
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and tissues
Total RNA extracted from five different human cell lines
was analysed by RT-PCR using different combinations of
exon-specific PPARδ primers. The presence of PPARδ tran-
scripts containing exons 2a, 2c and 2e in all cell lines was
confirmed by sequencing of PCR products (results not
shown). Real-time PCR was subsequently conducted to
estimate the relative amount of isoforms containing exons
2a, 2c and 2e among transcripts of PPARδ mRNAs. Sam-
ples of cDNA from human cell lines and from human
skeletal muscle tissue as well as from adult and fetal heart
tissues were subjected to TaqMan analysis using primers
and probes specified in Table 3. The analysis, illustrated in
Figure 2, showed that in all cell lines and tissues studied
the most common splice variant contained exons 2 and 4
joined together (Ex2:4) in the 5'-UTR. This variant was
expressed in the same order of magnitude as the total
amount of full length PPARδ detected with primers target-
ing exons 8 and 9 (Ex8:9). Transcripts containing exon 2
joined to exon 2a (Ex2:2a) were expressed at a much
lower level in all cell lines and tissues even though the
level of expression varied and was higher in HeLa cells
compared to skeletal muscle. The expression levels of
transcripts containing isoforms joining exons 2c and 3
(Ex2c:3) as well as exons 2 and 2e (Ex2:2e) were below the
detection limit in all the cell lines and tissues studied.
Analysis of promoter activities
The majority of the 5'-splice PPARδ transcripts identified
contain exon 1 in the 5'-end, indicating that the previ-
ously identified promoter region upstream of exon 1 is the
major region for transcriptional regulation of the human
PPARδ gene [25]. This was confirmed by transient trans-
fection assays in both Huh7 and HeLa cells using a range
of reporter gene constructs containing 2.6 kb to 48 bp of
the DNA sequence upstream of exon 1 (Figure 3). Maxi-
mum luciferase activity was obtained with the reporter
construct containing 171 bp of the promoter in both cell
lines (Figure 3A). Shorter constructs showed declining
activities with a major drop using the 48 bp construct.
Likewise, longer constructs showed decreasing luciferase
activities, indicating the presence of upstream transcrip-
tional repressor element(s).
Reporter gene constructs encompassing approximately 1
kb and 250 bp, respectively, of the 5'-regions of each of
the four putative transcription start sites (summarized in
Table 2 and illustrated in Figure 1B, 5'-UTR: H-K) showed
no or weak basal promoter activity in Huh7 and Hela cells
compared with the identified promoter region upstream
of exon 1 (Figure 3B). In silico analysis revealed a potential
PPRE located -86 to -74 bp upstream of the identified
alternative 5'-end within exon 2a. However, the two
reporter gene constructs (1 kb and 213 bp) containing this
PPRE were neither affected by overexpression of PPARδ
nor PPARα combined with isoform-specific ligands
GW501516 [26] and fibrates, respectively (results not
shown).
Translation efficiency of PPARδ 5'-splice variants
The impact of different 5'-UTRs on the translation effi-
ciency was analysed using coupled transcription/transla-
tion in a reticulocyte system (Promega). Plasmids
harbouring seven different 5'-UTRs (denoted 5'-UTR: A-G
in Figure 1B) placed in front of the PPARδ coding region
were analysed. The compiled results outlined in Figure 4
clearly show that transcripts with extended 5'-UTRs are
less efficiently translated into protein. The [35S]methio-
nine labelled translation products were resolved by SDS-
Table 3: TaqMan primers and probes used in this study
Name Target Sequence (5'-3')
Forward primers
TQEx2Fw exon 2 5'-GCTCACCAACAGATGAAGAC
TQEx2cFw exon 2c 5'-CCTCCTTGGAGACCAGCTA
TQEx8Fw exon 8 5'-GACCTGGCCCTATTCATTG
Reverse primers
TQEx2aRev exon 2a 5'-GCATTGTTCAGACTCTTGGT
TQEx2eRev exon 2e 5'-CAGGGAAGGTTCAAGGTCAA
TQEx3Rev exon 3 5'-GTATCTGACCCTGCTTTCCA
TQEx4Rev exon 4 5'-TCTGAACGCAGATGGACCT
TQEx9Rev exon 9 5'-ACCCGTGGAACGTTCATGA
Probes
Ex2:2aPr Exons 2:2a 5'-FAM-ACCTCCTACCCCTCGTTGGTG-TAMRA
Ex2:2ePr Exons 2:2e 5'-FAM-CACCAACGAGATTATCTTGAAGAC-TAMRA
Ex2c:3Pr Exons 2c:3 5'-FAM-CATTCCAGACCCTCACATAAGGA-TAMRA
Ex2:4Pr Exons 2:4 5'-FAM-TCCCATCAGCCTCGTTGGTGC-TAMRA
Ex8:9Pr Exons 8:9 5'-FAM-CTGGCCGGTCTCCACACAGAA-TAMRA
The primers and probes are annotated according to the target exons and exon/exon junctions in the human PPARδ gene, respectively.Page 4 of 17
(page number not for citation purposes)
BMC Molecular Biology 2007, 8:70 http://www.biomedcentral.com/1471-2199/8/70PAGE and subjected to autoradiography (Figure 4A).
Western blot analysis of the translated protein (Figure
4B), using a PPARδ specific antibody, showed immunore-
active proteins of compatible sizes (approximately 50
kDa) and intensities as the autoradiogram (Figure 4A).
The intensities of the [35S]methionine and Western blot
bands were quantified (Figure 4C). The alternatively
spliced human PPARδ 5'-UTRs differ in length and
number of AUGs. All identified upstream AUGs are
upstream open reading frames (uORFs) with an in-frame
stop codon within the 5'-UTRs. The 5'-UTR sequences
analysed harbour from 4 up to 14 upstream AUGs (Figure
4C). Strong inverse relationships were observed between
the number of AUGs and the measure of quantified trans-
lation efficiency (% Area) (R = 0.97 autoradiography; R =
0.90 Western blot) whereas that between the 5'-UTR
length and % Area was less pronounced (R = 0.84 autora-
diography; R = 0.71 Western blot).
Characterization of the truncated human PPARδ isoform 
(PPARδ2)
A 3'-spliced isoform of human PPARδ, formed by exon 9
skipping, has been reported from human placenta cDNA
clones [EMBL: BC007578 and BC002715, RefSeq Gen-
Bank: NM_177435]. Intron 8 is retained in the primary
transcript and an in-frame stop codon (UGA) in the
extended exon 8 encodes a protein lacking the C-terminal
82 amino acids of PPARδ, which constitutes the end of the
ligand-binding domain. The presence of a PPARδ2 tran-
script (identical to EMBL:BC007578 and BC002715) with
a polyadenylation signal 583 nt downstream of the stop
codon and a poly(A)tail attached was confirmed by 3'-
RACE using cDNA from placenta and adipose tissue (data
not shown). Adaptor linked transcripts with a 3'-end
within intron 8 were also obtained from pancreas cDNA,
however, poly(A)tail linked 3'-end transcripts could not
be confirmed.
PCR amplification of placenta and adipose 5'-RACE prod-
ucts enriched in either full-length PPARδ (PPARδ1) or
PPARδ2, respectively, revealed some differences regarding
TaqMan analysis of splice products in human cell lines and tissuesFigure 2
TaqMan analysis of splice products in human cell lines and tissues. 
Real-time PCR on cDNA from human cell lines (A-E) and human tissues (F-H) using primers and probes specified in Table 3 
was performed as described in "Methods". The following combinations of primers and probes were used for each TaqMan 
assay; TQEx8Fw, TQEx9Rev and Ex8:9Pr (Ex8:9); TQEx2Fw, TQEx4Rev and Ex2:4Pr (Ex2:4); TQEx2Fw, TQEx2aRev and 
Ex2:2aPr (Ex2:2a); TQEx2cFw, TQEx3Rev and Ex2c:3Pr (Ex2c:3); TQEx2Fw, TQEx2eRev and Ex2:2ePr (Ex2:2e). The result of 
each assay was normalized to the result of the Ex8:9 assay using the comparative CT method and presented as the mean rela-
tive expression levels (± SD).Page 5 of 17
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trated in Figure 5. A sequence within the coding region
(exons 4 to 8) as well as sequences encompassing exons 1
to 2 and exons 2 to 4 could be amplified using all 5'-RACE
products (Figure 5A–C). Transcripts containing exons 3,
2a, 2c, and 2e (Figure 5D–G) appeared, on the other
hand, to be absent in samples enriched in PPARδ2.
To analyse the trans-activating ability of PPARδ2, the
pFABPLUC reporter activity was investigated during over-
expression of PPARδ2 in the absence or presence of the
expression vector for full-length PPARδ (PPARδ1) and the
PPARδ specific ligand GW501516 [26]. Co-transfection of
pFABPLuc and the expression vector for PPARδ1 in HeLa
cells and treatment with GW501516 (10 nM and 100 nM)
increased the trans-activation ability in a dose-dependent
manner (Figure 6A). PPARδ2, on the other hand, had no
trans-activation ability in the presence of GW501516 (Fig-
ure 6A) but rather repressed the ligand-induced activation
of pFABPLuc reporter by PPARδ1 (Figure 6B). The expres-
sion of PPARδ1 and PPARδ2, respectively, in transfected
HeLa cells was confirmed by Western blot analysis show-
ing immunoreactive bands of expected sizes (approxi-
mately 50 kDa and 40 kDa) (Figure 6C). Gel retardation
analysis showed that full-length PPARδ1 binds to the
functional PPRE of the rat acyl-CoA oxidase gene in the
presence of RXR whereas PPARδ2 does not bind (Figure
7).
Comparative genomics
The human and mouse PPARδ RefSeqs were compared
and revealed an overall conserved pattern of exons and
introns. Two 5'-untranslated exons are conserved between
the human and mouse genes as illustrated in Figure 8. The
mouse exon 1A, previously reported to be positioned
upstream of exon 1B [27], was found to be located down-
stream of exon 2 in the mouse RefSeq. The two genes har-
bour six and three, respectively, species-specific 5'-
untranslated exons. All these exons, except for mouse
exon 1C, are located between exon 2 and the first coding
exon, a region with no apparent sequence conservation
between species. Comparative analysis using the ECR
Browser tool [28], on the other hand, revealed regions of
conservation relative to the human PPARδ gene in the
chimpanzee, rhesus macaque and dog orthologous genes
as depicted in Figure 9. The genomic positions of the
Reporter gene constructs and relative promoter activitiesFigu e 3
Reporter gene constructs and relative promoter activities. A schematic view of the different PPARδ reporter gene 
constructs and the luciferase activities obtained after transient transfection in Huh7 (black bars) and HeLa cells (white bars), set-
ting the value of the promoterless control plasmid to 1. A. Luciferase assays on reporter gene constructs containing from 2.6 
kb down to 48 bp of the region upstream of exon 1 in the PPARδ gene compared to empty pGL3 vector. B. Luciferase assay on 
reporter gene constructs containing approximately 1 kb and 250 bp of the upstream regions of four identified alternative 5'-
ends summarized in Table 2 and illustrated in Figure 1B (5'-UTRs: H-K), compared to empty pGL3 vector.Page 6 of 17
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served regions and of exons 2b, 2c and 2d within repeti-
tive regions are indicated in Figure 9. Repetitive regions
are masked prior to comparative analysis of conserved
region in the ECR Browser alignment and thus excluded
from comparison. Using ClustalW alignment the masked
regions harbouring the sequences of the orthologous
exons 2b and 2c in chimpanzee, macaque and dog
revealed an overall sequence identity of 98%, 59% and
15%, respectively, compared with the human PPARδ
counterpart, as indicated in Figure 9. The masked region
containing exon 2d, on the other hand, showed no
sequence similarity between species. Identity scores and
lengths of matching sequences to the human exons iden-
tified in the PPARδ gene of chimpanzee, macaque and dog
are given in Table 4.
The overall sequence conservation between human and
chimpanzee PPARδ genes is pronounced. Moreover, the
NCBI HomoloGene database displays two isoforms of
chimpanzee PPARδ mRNA, denoted isoforms 3 [Gen-
Bank: XM_001172224] and 4 [GenBank:
XM_001172238], which harbour spliced forms of exon
2a.
The major process whereby new exons evolve is consid-
ered to be exonization of intronic sequences [29,30]. The
primate specific Alu-elements can be exonized through a
small number of mutations. Using the RepeatMasker to
analyse the human PPARδ gene, exon 2b was found to ful-
fil the criteria of being an Alu-derived exon [31,32]. Simi-
lar antisense Alu-elements are present in the
corresponding region of the chimpanzee and macaque
genes, both with mutations to enable exonization of
orthologous exon 2b. A second exon-associated Alu-ele-
ment is present in the 5'-end of exon 2c, close to the alter-
native 5'-end identified in pancreas. This Alu-element is
conserved in the chimpanzee PPARδ gene. Exon 2d is
Table 4: Sequence identity scores of human PPARδ exons in 








Exon 2 (84) 98 (84) 97 (84) 85 (84)
Exon 2a (641) 98 (641) 95 (639) 82 (622)†
Exon 2b (119) 99 (119) 74 (122) -
Exon 2c (883) 98 (852) -* 77 (507)†
Exon 2d (312) - - -
Exon 2e (115) 99 (129) 89 (66)† 58 (141)‡
Exon 3 (96) 99 (96) 95 (84)† 39 (103)‡
Coding exons 99 95 91
Identity scores were calculated by ClustalW alignments and include 
scores for the novel human PPARδ exons and human exon 2, exon 3 
and coding exons (1326 bp) for comparison. Exon 1 was not included 
since complete sequence information for this exon is not available for 
all species. Scores given in italic numbers indicate a sequence without 
conserved splice junctions.
* Sequence comparison precluded by unsequenced gaps in the 
macaque PPARδ gene
†A full-length exon is not conserved. Identity scores are given for a 
sequence homologous to the 3'-region of the comparable human 
exon
‡ An orthologous exon was not identified. Identity scores are given 
for a sequence with the highest homology scores within the genomic 
region comparable to the location of the human exon
The compiled results of the in vitro coupled transcription/translation analy isFigure 4
The compiled results of the in vitro coupled transcrip-
tion/translation analysis.
A. Denaturing gel analysis of [35S]methionine labelled transla-
tion products visualized by autoradiography. Samples A-G 
correspond to the in vitro-translated products obtained using 
Quick CoupledTranscription/Translation System (Promega) 
as described in "Methods" with plasmid DNA templates con-
taining human PPARδ with the 5'-UTRs denoted A-G in Fig-
ure 1B. The composition of untranslated exons in the 5'-
UTRs are: (A) Exon 1, (B) Exons 1+2, (C) Exons 1+2+3, (D) 
Exons 1+2+2e+3, (E) Exons 1+2+spliced 2a(90 bp)+3, (F) 
Exons 1+2+2a, (G) Exons 1+2+2a+3. BL is a negative control 
sample without template and Luc is a positive luciferase con-
trol sample. 
B. Western blot analysis of the products of the translation 
reactions probed with the polyclonal PPARδ specific anti-
body IMG-3297. The sizes of standard molecule markers are 
given on the left side (A and B). 
C. Quantification of the [35S]methionine labelled band intensi-
ties was performed on the autoradiographic (grey bars) and 
Western blot (white bars) bands using the NIH ImageJ soft-
ware. The relative intensities of signals (% Area) were calcu-
lated setting the signal of construct A to 100%. The number 
of upstream AUGs and the total length of each 5'-UTR is 
given below each bar of calculated signal.Page 7 of 17
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PPARδ isoform-specific variability among 5'-UTRsFigure 5
PPARδ isoform-specific variability among 5'-UTRs. 5'-RACE products enriched in either full-length PPARδ (PPARδ1) or 
PPARδ2 obtained using cDNA from placenta (Pl) and adipose tissue (A) according to "Methods" were used as templates for 
PCR reactions with untranslated exon/exon primer pairs, and with primers that amplify over exons in the coding region as 
control. A. Exon 4 to 8 (769 bp) amplified using Ex4Fw and Ex8Rev; B. Exon 1 + 2 (139 bp) amplified using Ex1:2Fw and Ex2Rev; 
C. Exon 1 + 4 (255 bp) amplified using Ex1:2Fw and Ex4:2Rev; D, Exon 3 + 4 (103 bp) amplified using Ex3Fw and Ex4:2Rev; E, 
Exon 2 + 2a (565 bp) amplified using Ex2Fw and Ex2a:1Rev;F, Exon 2c + 4 (399 bp) amplified using Ex2cFw and Ex4:1Rev;G, 
Exon 2e + 4 (326 bp) amplified using Ex2eFw and Ex4:2Rev. The sizes of the major bands obtained are indicated and the iden-
tities of the products were confirmed by sequencing.
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Trans-activation ability of PPARδ2 investigated by transient transfection of HeLa cellsFigure 6
Trans-activation ability of PPARδ2 investigated by transient transfection of HeLa cells. A. Co-transfection of pFAB-
PLuc reporter construct (200 ng) with expression vector for either PPARδ1 (100 ng), PPARδ2 (100 ng) or irrelevant plasmid 
DNA pUC19 (100 ng), untreated (control) or treated with 1 nM, 10 nM or 100 nM of the PPARδ specific ligand GW501516. B. 
Co-transfection of pFABLuc reporter construct (200 ng) with constant amount of expression vector for PPARδ1 (50 ng) and 
increasing concentrations of the expression vector for PPARδ2 (50 to 200 ng) and treatment with 10 nM or 100 nM 
GW501516. Transfection of the pFABLuc vector alone was used as a control. Plasmid DNA pUC19 was added to ensure equal 
amount of DNA in all transfections. Plasmid pSV-β-galactosidase control vector (Promega) (260 ng) was co-transfected in all 
experiments for normalization of the transfection efficiency. The data presented are the mean (± SD) luciferase/β-galactosidase 
ratios of three independent transfections determined in quadruplicates. The activities are expressed as relative values setting 
the value of untreated control to 1 (A) or the value obtained without PPARδ2 expression plasmid to 1 (B). C. Western blot 
analysis with nuclear extracts prepared from untransfected HeLa cells (Contr) and HeLa cells transfected with the expression 
vectors encoding PPARδ1 or PPARδ2, respectively, using a PPARδ antibody raised against the N-terminal region of the nuclear 
receptor (sc-7197, Santa Cruz Biotechnology). The sizes of standard molecule markers are given on the left side.
BMC Molecular Biology 2007, 8:70 http://www.biomedcentral.com/1471-2199/8/70located within a SVA element (SVA_D), named after its
main components; short interspread nuclear element
(SINE), variable number of tandem repeats (VNTR) and
Alu [33]. In general this subfamily of SVA elements is
believed to predate the divergence of human and chim-
panzee lineage but is not present in the chimpanzee
PPARδ gene. Exon 2d is thus truly a human specific exon.
Homologues to the human PPARδ2 isoform are presented
in the NCBI GenBank as isoform models for both chim-
panzee and macaque [GenBank: XM_001172194 and
XM_001116671]. The stop codon and the polyadenyla-
tion signal in intron 8 are fully conserved in the PPARδ
genes of these primates. The potential 3'-UTRs of chim-
panzee and macaque PPARδ2 show 99% and 94% overall
sequence identity to the human counterpart, respectively.
This pronounced sequence conservation indicates that
PPARδ2 could be a primate specific isoform.
Discussion
A diversity of 5'-UTRs derived from alternative splicing
was identified among human PPARδ mRNAs in this
study. The majority of 5'-UTRs have exon 1 in the 5'-end,
and reporter gene analysis using Huh7 and HeLa cells sug-
gests that the main promoter of human PPARδ is posi-
tioned upstream of exon 1. As previously reported [25],
this promoter does not have a consensus TATA-box but is
rich in potential Sp-1 binding elements, a typical feature
for house-keeping genes. This region contains evolution-
ary conserved areas between the human and mouse
PPARδ genes. Alternative promoters could, however, be
present in the human PPARδ gene, as is the case for the
mouse orthologous gene [27]. Contrary to this assump-
tion, reporter gene analysis using Huh7 and HeLa cells
showed a low promoter activity related to only one of the
four alternative promoter regions tested. Analysis of other
cell types could, however, provide a different result. The
identified alternative 5'-ends might represent tissue- or
developmental-specific alternative transcription starts
sites or be the products of as yet unknown post-transcrip-
tional processing. A tissue-specific alternative transcrip-
tion start site could apply to one alternative 5'-end, which
was detected only in cDNA from pancreas.
Several levels of regulation of PPAR activity have been
reported such as phosphorylation by kinases that affects
the transactivation potential and ubiquitin-proteosome
degradation, a mechanism to arrest transcriptional activa-
tion [26,34-38]. The post-transcriptional regulation by 5'-
splicing suggested here for human PPARδ and previously
reported for the mouse orthologous gene [27] could rep-
resent one additional level of regulation. At least eight
exons can be included in the 5'-UTR region of human
PPARδ transcripts by alternative splicing; the previously
identified exons 1, 2 and 3 [25] and the five exons (2a-2e)
identified in this study. The untranslated human PPARδ
exons are not mutually exclusive but rather appear to be
spliced-in forming a diversity of 5'-UTRs containing any
combination of exons. In addition to the splice variants
discussed and depicted in Figure 1B, ten more combina-
EMSA to assess the binding properties of PPARδ isoform 1 and 2 to ACO-PPREFigure 7
EMSA to assess the binding properties of PPARδ iso-
form 1 and 2 to ACO-PPRE. Gel retardation assay was 
performed with end-labelled ACO-PPRE in the presence (+) 
or absence (-) of in vitro transcribed/translated human 
PPARδ1, PPARδ2, RXRα or mock lysate as described in 
"Methods". Unlabelled ACO-PPRE was added at 100-fold 
molar excess for competition. Supershift experiments were 
carried out using a PPARδ antibody directed against the N-
terminal region of human PPARδ. Arrows indicate the posi-
tions of the shifted and the supershifted bands. None of the 
receptors (PPARδ1, PPARδ2 or RXRα) alone could be 
supershifted in the presence of the PPARδ antibody (data not 
shown).Page 10 of 17
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Conservation profiles of the PPARδ gene using the ECR Browser toolFigure 9
Conservation profiles of the PPARδ gene using the ECR Browser tool. The conservation profiles (percent identity 
cut-off of 50% to 100%) of the human PPARδ gene in comparison with the mouse (Mus musculus; chr17), dog (Canis familiaris; 
chr12), macaque (Macaca mulatta; chr4) and chimpanzee (Pan troglodytes; chr6) orthologous genes are shown. Conserved 
sequences are defined as coding exons (blue), untranslated exons (yellow) and introns (pink). The locations of the novel 
untranslated human exons (2a-2e) in the PPARδ gene are indicated by arrows. The percent identity of the masked (unaligned) 
sequence harbouring exons 2b and 2c obtained by ClustalW alignment is indicated in the defined area, likewise the lack of iden-
tity over the masked region containing exon 2d is indicated by horizontal lines. A schematic view showing the locations of pre-
viously identified exons in human PPARδ gene are aligned above the conservation profile for orientation.
Comparing the organization of the human and mouse PPARδ genesFigure 8
Comparing the organization of the human and mouse PPARδ genes. A. The human PPARδ gene (85 kb) located on 
chr6, B. The mouse ortologue gene (70 kb) located on chr17. The overall difference in length can be accounted for by the 63 
kb versus 50 kb separating exon 2 and the first coding exon (4 or 3) in human and mouse genes, respectively. The relative posi-
tions of exons along the genes are given, specifying exons that are conserved between species (white boxes) and species-spe-
cific exons (black boxes). Arrows indicate the position of the initiation codon ATG and the stop codon TAA, respectively, with 
the intervening coding exons.
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and the previously reported untranslated exons 1, 2 and 3
have been observed, either by sequencing of PCR products
in this study or in data from the human EST-data base.
The newly identified exons are positioned within the 63
kb long sequence separating exon 2 and the first coding
exon. Interestingly, all PPAR isoforms share a similar gene
organization with long introns separating untranslated
exons from coding exons. The presence of several new
splice variants affecting the 5'-UTR region of PPARγ was
recently reported [39]. Likewise multiple isoforms of
human PPARα with variable 5'-UTRs are presented in the
NCBI HomoloGene database.
Different combinations of 5'-untranslated human PPARδ
exons form 5'-UTRs of various length and numbers of
upstream AUGs. The originally postulated scanning
mechanism for initiation of translation predicts that
translation should be initiated at the first AUG codon
closest to the 5'-end of the mRNA [40]. However,
upstream AUGs that are followed by a run of codons that
ends in a termination codon within the 5'-UTR, so called
upstream open reading frames (uORFs), play a role in
translational regulation [41,42]. The strong correlation
between the number of upstream AUGs and the observed
translation efficiency indicates that the regulation of the
yield of PPARδ per unit mRNA involves uORFs. An influ-
ence on translation by GC rich regions with a potential to
form stable secondary structures in the more extended 5'-
UTRs cannot be ruled out. The possibility of an initiation
of translation by internal ribosomal entry sites (IRES) that
circumvents upstream AUG codons and secondary struc-
tures is intriguing. The presence of IRES in the 5'-UTRs of
many growth regulatory genes is believed to provide a
means for the tuning of their translation in time and space
and in response to relevant stimuli [43].
Our results and available human EST data suggest a ubiq-
uitous occurrence of the newly identified exons in human
PPARδ mRNAs. Quantification using real-time PCR, how-
ever, showed that the overall preferred 5'-UTR is short,
containing only exons 1 and 2, thus representing the
majority of the human PPARδ transcripts. Besides this,
only mRNA isoforms containing exon 2a are present in
measurable amounts. Considering that the presence of
full-length exon 2a contributes substantially to the
reduced translation efficiency, it is tempting to speculate
that occurrence of exon 2a might be of importance for the
functional roles of human PPARδ.
The generation rate of new exons has been calculated to
approximately 2.71 × 10-3 per gene per million years [44].
Most new exons are considered to originate from exoniza-
tion of intronic sequences and appear in minor splice
forms, which is in agreement with the finding in this
study. An important question that remains to be answered
is whether the low-abundant splice variants containing
the newly identified exons represent biologically signifi-
cant and functional isoforms. Comparative genomics was
used as a guide to identify conserved sequence element,
considering that functional regions generally are under
strong selection pressure to stay unchanged. The previ-
ously identified untranslated exons 1 and 2 are highly
conserved between species whereas the newly identified
human PPARδ exons are either human- or primate-spe-
cific exons. Exon 2d was identified as a human-specific
exon. All other novel exons are highly conserved in chim-
panzee whereas only two exons (exons 2a and 2b) show
the same high conservation in macaque. Likewise, all fea-
tures related to the four alternative 5'-ends identified for
the human PPARδ are fully conserved in chimpanzee
whereas only one, the 5'-end related to exon 2a, is pre-
served in the macaque. At present, however, there is no
available EST data to predict alternative splicing or pro-
moter usage of PPARδ in chimpanzee or macaque.
The sequence of exon 2a appears to be the most conserved
of the five new human PPARδ exons. All features related
to this exon, including internal splice junctions and a
putative 5'-end, are fully conserved in both the chimpan-
zee and macaque genes. Alternative splicing involving a
homologous exon 2a in chimpanzee is suggested by avail-
able PPARδ isoforms for this species. The overall conser-
vation of the exon 2a sequence is surprisingly high in the
dog gene. However, it is highly unlikely that an ortholo-
gous exon is spliced in this species.
Taken together, it is likely that transcripts with a short 5'-
UTR provide a constant basal level of PPARδ synthesis.
Transcripts with extended 5'-UTRs, such as the mRNA iso-
forms containing full-length exon 2a, with multiple AUG
codons and potential secondary structures, could provide
a spatio-temporal regulation of protein expression during
for example growth, development, differentiation and
stress. It has been reported that dysregulation of key pro-
teins regulating growth and differentiation via modula-
tion of 5'-UTR activity plays a role in the development or
progression of various forms of cancer [43]. Whether
mechanisms related to alternative splicing of PPARδ could
contribute to the conflicting findings regarding the role of
this nuclear factor in cancer development remains to be
investigated [13]. Likewise, the role of alternative promot-
ers in the regulation of human PPARδ gene expression is a
matter to consider in future studies.
The possibility of a dominant negative variant of the
human PPARδ adds to the complexity of PPARδ as a tran-
scriptional regulator. The alternative polyadenylation sig-
nal and premature stop-codon in human PPARδ intron 8
are not conserved in mouse, indicating that this isoform isPage 12 of 17
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of PPARα and PPARγ [45,46]. Suggested orthologs of the
human PPARδ2 in chimpanzee and macaque, on the
other hand, indicate that this could be a primate-specific
isoform. Investigation of 5'-UTRs among human PPARδ2
transcripts shows that this isoform, similar to full-length
PPARδ, is preferentially transcribed from a promoter
upstream of exon 1. Since the variability among 5'-UTRs
of PPARδ2 is less pronounced, this isoform appears to be
less subjected to alternative splicing and thus translational
regulation.
Transcripts of PPARδ2 were identified in placenta and adi-
pose tissue. The occurrence and functional implications of
PPARδ2 transcripts translated into protein in different
cells and tissues, however, remains to be elucidated. Here
we have shown for the first time in vitro that the isoform
PPARδ2 represses the trans-activating ability of full-length
PPARδ. The mode of action of dominant negative nuclear
receptors in general is either competition for binding of
DNA, auxiliary factors and cofactors or an effect on sub-
cellular localization. A dominant negative mutant of the
full-length mouse orthologous of PPARδ (E114P) has
been tested in a similar setting with a PPRE reporter gene
construct and GW501516, and shown to dose-depend-
ently inhibit PPARδ induced luciferase activity. Contrary
to PPARδ2 this full-length mutant is suggested to bind lig-
and and PPRE but remains in a repressive form and acts
by competing with wild type PPARδ for binding to DNA
[47,48]. The result of the mobility shift assay presented
here indicates that PPARδ2 exerts its inhibitory properties
by another mechanism than competition for binding to
PPREs.
Conclusion
The main finding of this study is the demonstration of
multiple 5'-UTR splice variants of PPARδ mRNA that can
influence the translation capacity. Moreover, the alterna-
tive splicing of human PPARδ is also reflected by the gen-
eration of a dominant negative isoform. Considering that
PPARδ is widely expressed, a master regulator of gene
transcription and acts as a metabolic sensor, proper
understanding of the factors affecting the expression level
and activity of this nuclear receptor is of crucial impor-
tance. Dysregulation of alternative splicing might pro-
mote human disease [49]. In the case of human PPARδ,
this would entail dysregulation of protein expression with
effects on both the trans-activating and repressor poten-
tials of PPARδ.
Methods
Oligonucleotides and TaqMan probes
Oligonucleotides used in this paper were purchased from
Proligo (France) and Thermo Hybaid (Germany). The
sequences of RACE and PCR primers are listed in Table 5
and TaqMan primers and probes are listed in Table 3.
Rapid amplification of cDNA ends (RACE)
Marathon-Ready cDNAs (Clontech) from human pla-
centa, pancreas and adipose tissue were utilized for RACE
studies according to the manufacturer's instructions. Two
sequential rounds of 5'-RACE were carried out with the
reverse gene-specific primer (GSP) Ex7Rev, followed by
Ex6Rev or Ex3Rev in combination with adapter primers
(AP1 and AP-2; Clontech). Purified fragments were
sequenced using Big Dye Terminator Kit and an automatic
sequencer (Genetic Analyzer 3100, Applied Biosystems).
Nested PCR was subsequently performed using primers
Ex5Rev, Ex4:1Rev, Ex2a:1Rev, Ex2a:2Rev, Ex2cRev and
Ex2eRev combined with the adapter primer AP2.
Sequencing was performed either directly on the PCR
products or on samples of gel-purified fragments when
multiple bands were obtained.
Another round of 5'-RACE was conducted on Marathon-
Ready cDNAs using either a full-length PPARδ (PPARδ1)
primer (Ex9:1Rev) or a PPARδ2 specific primer (In8:1Rev)
in combination with the adapter primer AP1. Further
rounds of PCR on these 5'-RACE products, thus enriched
in either PPARδ1 or PPARδ2, were performed using exon/
exon specific primer pairs specified in the Result section
(Figure 5).
Two sequential rounds of 3'-RACE were carried out using
Marathon-Ready cDNAs and the gene-specific forward
primers Ex8:1Fw and In8Fw in combination with adapter
primers AP1 and AP-2, respectively. Sequencing was per-
formed on PCR products as described above.
RNA extraction, reverse transcription, PCR and real-time 
PCR analysis
Total RNA was extracted using RNeasy system (Qiagen)
from a panel of human cell lines; the human hepatocellu-
lar carcinoma cell lines HepG2 and Huh7, the cervical epi-
thelioid carcinoma cell line HeLa, the human acute
monocytic leukaemia cell line THP-1 and kidney epithe-
lial carcinoma cell line A498. One microgram of total
RNA was reverse transcribed with a poly-dT primer using
Superscript II (Invitrogen) according to the manufac-
turer's instructions. First strand cDNAs were subjected to
PCR using exon specific primer pair combinations (Table
5). The PCR cycles were as follows: 94°C for 3 min fol-
lowed by 36 cycles of 94°C for 20 sec, 55°C for 30 sec,
72°C for 30 sec, and finally 72°C for 10 min. Sequencing
was performed on PCR products as described above. Real-
time PCR (TaqMan analysis) was performed on cDNA
from human cell lines and tissues according to the manu-
facturer's instructions (Applied Biosystem, USA) and the
reaction conditions involved denaturation for 10 min atPage 13 of 17
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and 1 min at 60°C. Primers and probes are listed in Table
3. Two different cDNAs obtained using total RNA from
each cell line (described above) or tissue (Clontech) were
analysed twice and determined in triplicates using an ABI
prism 7000 (Applied Biosystem). Standard curves were
run for all assays to ensure consistent amplification effi-
cacy. All variants were normalised to the Ex8:9 assay using
the comparative CT-method (User Bulletin #2, December
11, 1997 (updated 10/2001); ABI PRISM 7700 Sequence
Detection System) and presented as relative expression
levels.
Reporter gene constructs, transient transfections and 
luciferase assays
A luciferase reporter gene construct covering the proximal
promoter region of the human PPARδ gene upstream of
exon 1, from -733 to + 44 cloned into pGL3 Basic
(Promega) (hereafter referred to as the -733 bp construct)
has previously been described [50]. Additional constructs
covering longer (2.6 kb and 1.5 kb) and shorter sequences
(171 bp, 61 bp and 48 bp) of this promoter were created
from restriction enzyme digests of a genomic PPARδ clone
[25] and the -733 bp construct. Likewise, genomic
upstream sequences (approximately 1 kb and 250 bp) for
each of the four alternative transcription start sites identi-
fied in this study were PCR amplified and cloned into
pGL3 Basic.
The Huh7 and HeLa cell lines were maintained in Dul-
becco's modified Eagle's medium (D-MEM 1g/ml glucose,
Invitrogen) supplemented with 10% fetal bovine serum,
penicillin (100 units/ml) and streptomycin (100 ug/ml)
at 37°C in 5% CO2 in air. Approximately 1 × 105 cells/well
were plated on a 24-well plate and transiently transfected
after 24 h with 100 ng of the reporter gene constructs or
empty vector using Lipofectamin (Invitrogen) according
to the manufacturer's protocol. Plasmid pSV-β-galactosi-
dase control vector (Promega) (260 ng) was co-trans-
fected for normalization of the transfection efficiency.
After 24 h, cells were washed, lysed and luciferase activity
was measured as previously described [51]. The β-galac-
tosidase enzyme assay system (Promega) was used for
measuring the β-galactosidase activity in cell lysates
Table 5: Oligonucleotide primers used for RACE and PCR in this study
Name Target Sequence (5'-3')
Forward primers
Ex1:1Fw exon 1 5'-TTAAGCTTGGTACCCGCGGACCTGGGGATTAATGG
Ex1:2 Fw exon 1 5'-AATTCTGCGGAGCCTGCGG
Ex2Fw exon 2 5'-ACGTGATACTCACACAGTGG
Ex2a:1Fw exon 2a 5'-GGAGCTCCAGGGAATACAATGTTCA
Ex2a:2Fw exon 2a 5'-CAGGCCCAGTGGCAGCAAT
Ex2cFw exon 2c 5'-GGCACTTGATGCTGTTGAATGGAG
Ex2eFw exon 2e 5'-CCAGCTCTCCTTGACCTTGAACCTT
Ex3Fw exon 3 5'-AACTGAAGCCCGTGGAGCA
Ex4Fw exon 4 5'-GACCACAGCATGCACTTCCT
Ex8:1Fw exon 8 5'-AGTGGCTTTGTCACCCGTGAGTTCCTG
Ex8:2Fw exon 8 5'-TCCGCAAACCCTTCAGTGATA
In8Fw intron 8 * 5'-GGCTGAGCCAGGAGAATCGCTTGA
Reverse primers
Ex2Rev exon 2 5'-CTCGTTGGTGCATCTGTCTTCA
Ex2a:1Rev exon 2a 5'-CGCTCAGGAGGTACTTTGACCTCTTCC
Ex2a:2Rev exon 2a 5'-GCTCAGGGATGAACTGGACAACTGAC
Ex2cRev exon 2c 5'-ATGCTTCTGCTCAGAACCCAGCTCTCA
Ex2eRev exon 2e 5'-AAGAGTGAAGGGCAGCTGAGTCCTGA
Ex3Rev exon 3 5'-GAAGCAGTCCTGTAGAGATCAT
Ex4:1Rev exon 4 5'-CCCAGTCATAGCTCTGGCATCGTCT
Ex4:2Rev exon 4 5'-TGGCTGCTCCATGGCTGATCT
Ex5Rev exon 5 5'-GTCACAGCCCATCTGCAGTT
Ex6Rev exon 6 5'-CACTTCTCGTACTCCAGCTTC
Ex7Rev exon 7 5'-TGCCACCAGCTTCCTCTTC
Ex8Rev exon 8 5'-CCAGCCCCTTCTCTGCCT
Ex9:1Rev exon 9 5'-CTGGAGCAGAGGGTGCAGCGAGGTCT
Ex9:2Rev exon 9 5'-ATGGCATGCCCAGCTGTGC
In8:1Rev intron 8* 5'-GATTACAGGTGTGAGCCACCACGTCTG
In8:2Rev intron 8* 5'-CCCACATTAACATGACAGCAT
The primers are annotated according to the target exon or intron in the human PPARδ gene.
* Comparable to the 3'-UTR of PPARδ2Page 14 of 17
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ties were determined in quadruplicates and the data pre-
sented are based on the mean (± SD) luciferase/β-
galactosidase ratios of three independent transfections,
setting the value of empty vector to 1.
Coupled transcription/translation
A fragment covering the full-length PPARδ mRNA
sequence from exon 1 to the 3'-UTR was amplified using
Marathon placenta cDNA and primers Ex1:1Fw (introduc-
ing a KpnI restriction site in the 5'-end) and Ex9:2Rev. The
fragment was cloned into the pTNT vector (Promega)
using the restriction sites KpnI and SmaI in the vector and
KpnI and MscI in PPARδ, respectively. Variable 5'-UTRs
upstream of exon 4 were introduced using the primer-
based KpnI site in the 5'-end of exon 1 and an NcoI site in
exon 4. The 5'-UTR sequences were amplified using Mara-
thon cDNAs and combinations of exon specific primers
Ex1:1Fw, Ex2a:1Fw, Ex2a:2Fw, Ex2eFw, Ex2eRev, Ex3Rev
and Ex4:2Rev. Longer 5'-UTRs were amplified in two
pieces, subcloned in PGEM-T vector (Promega) and
ligated together prior to being introduced in the 5'-end of
PPARδ in pTNT vector. Coupled in vitro transcription and
translation was performed on these plamids using a TNT
Quick Coupled Transcription/Translation System
(Promega) and [35S]methionine (Amersham) according
to the manufacturer's instructions. The [35S]methionine
labelled products were separated by 10% SDS-polyacryla-
mide gel electrophoresis (SDS-PAGE), subjected to auto-
radiography and analysed on a PhosphorImager scanner
(Fuji film Bas-2500, Australia). The in vitro translated
products were also subjected to Western blot analysis
under reducing conditions on 10% SDS-PAGE as
described by Laemmli [52] using the polyclonal PPARδ
specific antibody IMG-3297 (Nordic Biosite, Sweden) and
a horseradish peroxidase-labelled secondary antibody.
Detection was performed with the ECL Advanced Western
blot detection system (Amersham). Both the autoradio-
graphic and Western blot bands were quantified using the
NIH ImageJ software [53]. The amounts of plasmids used
(1 µg) were within a range of saturating conditions where
the outcome of the transcription/translation reactions was
independent on the differences in target DNA concentra-
tion introduced by the different lengths of the 5'-UTRs.
Expression vectors for PPARδ, transient transfections and 
Luciferase assays
The expression vector for full-length PPARδ (PPARδ1)
under the control of the human cytomegalovirus (CMV)
promoter was a kind gift of Dr CN Palmer and is described
elsewhere [54]. The expression vector for PPARδ2 was cre-
ated using an EcoRV site in the coding region, common to
both PPARδ1 and 2, and replacing the downstream
sequence of the expression vector with the corresponding
3'-sequence of PPARδ2. The 3'-sequence of PPARδ2 was
obtained by PCR using a genomic clone of PPARδ as tem-
plate [25], and the forward primer Ex8:2Fw and reverse
primer In8:2Rev. The reporter construct pFABPLUC con-
taining four copies of the PPRE from the human liver
FABP gene in front of the HSV-TK promoter is described
elsewhere [54]. Growth and transfection of HeLa cells,
Luciferase assay, and β-galactosidase assay were per-
formed as described above. Nuclear extract prepared as
previously described [55] from HeLa cells transfected with
the expression vectors for PPARδ1 and PPARδ2, respec-
tively, was subjected to Western blot analysis as described
above, using the PPARδ antibody sc-7197 (Santa Cruz
Biotechnology). Nuclear extract prepared from untrans-
fected HeLa cells was used as a negative control.
Electrophoretic mobility shift assay, EMSA
The binding properties of PPARδ1 and PPARδ2, respec-
tively, to the functional PPRE of the rat acyl-CoA oxidase
gene with and without the heterodimer partner RXR were
investigated by EMSA. Human PPARδ1 and PPARδ2,
cloned into the TNT vector, and TNT-hRXRα (a kind gift
from Dr Glinghammar, AZ, Sweden) were in vitro tran-
scribed/translated using the rabbit reticulocyte lysate sys-
tem (Promega) as previously described but with
unlabelled methionine. Incubation for EMSA was con-
ducted as previously described [56] using 6 µl of in vitro
produced PPARδ1 or PPARδ2 with 2 µl of RXRα or mock
lysate produced using an empty vector, in a total volume
of 20 µl (2 µg poly(dI-dC), 0.75 mM EDTA pH 8.0, 18
mM HEPES pH 7.9, 0.5 mM dithiothreitol, 4% Ficoll),
and [γ-32P]-end labelled double stranded ACO-oligo (5'-
ggaccAGGACAaAGGTCAcgttcgg-3')[57]. For competition,
a 100-fold molar excess of unlabelled double stranded
ACO-oligo was added. A PPARδ antibody sc-7197 was
used for supershift. This antibody, directed against the N-
terminal region (epitope 2–75) of human PPARδ, was
shown to detect both variants of in vitro translated PPARδ
using Western blot (data not shown). DNA-protein com-
plexes were applied to a 6% polyacrylamide gel and run
for 4 hours at 200V in 0.25 × TBE at 4°C. The gel was
dried, subjected to autoradiography and analysed on a
PhosphoImager scanner.
Bioinformatics and comparative genomics
The NCBI human Genome Browser, the human EST-
search tool and homologue RefSeq of PPARδ were pro-
vided by NCBI [58]. The Evolutionary Conserved Regions
Browser tool (ECR Browser) [59] was used to identify
sequence conservation between species, ClustalW [60] for
sequence alignments and sequence identity scores and the
RepeatMasker [61] to unravel repetitive elements in
PPARδ genes. Localization and extraction of relevant
sequences for comparative analysis between species was
performed using the ECR Browser tool and defined
regions were subsequently extracted from the PPARδ genePage 15 of 17
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exon sequences using ClustalW.
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